Secondary progressive MS therapy MIS416 dosing trial....

[MSUK]

Secondary progressive MS therapy MIS416 dosing trial underway

New Zealand and Australia-based Innate Immunotherapeutics Limited, a medical biotechnology company with offices in Sydney and Auckland, has issued an update regarding its Phase 2B trial for secondary progressive multiple sclerosis (SPMS) and other recent activities.

The Phase 2B MIS416 trial Patient dosing with MIS416 is now underway at the West Australian Neuroscience Institute (WANRI) in Perth and at Nucleus Network’s AMREP Centre for Clinical Studies in Melbourne. Each site has dosed their first two patients with several more patients due to commence treatment this month. A Brisbane site, the Wesley-St. Andrew’s Research Institute (WSARI), will be initiated on November 12th and will start recruiting patients shortly thereafter............ Read More- http://www.ms-uk.org/MIS416